Haemonetics' Q3 Revenue Hits $339M as Fund Highlights Earnings Beat, Shares Slide 20%
In Q4 2025 Aristotle Small Cap Equity Fund returned 1.96%, citing Haemonetics’ strong earnings beat and competitive plasmapheresis position as a top contributor. Haemonetics reported Q3 revenue of $339 million (YTD $988 million), a $2.68 billion market cap, and its shares fell 19.97% over one month and 7.38% over 12 months.
1. Aristotle Small Cap Equity Fund Performance
Aristotle Capital Boston’s Small Cap Equity Fund delivered a 1.96% return in the fourth quarter of 2025, slightly trailing the Russell 2000’s 2.19% gain. Strong security selection boosted performance, with Haemonetics cited as one of the fund’s leading contributors, while allocation choices modestly detracted.
2. Haemonetics Financial Results and Stock Movement
Haemonetics reported third-quarter revenue of $339 million, lifting year-to-date revenue to $988 million and supporting its $2.68 billion market capitalization. Despite the earnings beat, shares declined 19.97% over the past month and 7.38% over the last year.
3. Competitive Position and Outlook
The fund highlighted Haemonetics’ leading role in the global plasmapheresis market and its recent earnings outperformance. It noted that increased research and development investments should bolster product innovation and drive shareholder value over the next several years.